7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research

Conflict of Interest, Research Misconduct & Fraud

Quick Reference: A conflict of interest is a circumstance in which a secondary interest — money, career advancement, personal relationship, institutional loyalty — could reasonably be seen to compromise judgement about a primary interest, which in clinical research is participant welfare and the reliability of results. Misconduct is an act. Conflicts are disclosed and managed; misconduct is investigated and sanctioned. Confusing the two is the most common exam error in this area.

Why this is tested

The ACRP-CP Exam Content Outline lists 1N, "Conflict of interest in clinical research" and 1O, "Fraud and misconduct" as separate knowledge statements in Domain 1, and includes the task statements "Evaluate potential conflicts of interest" and "Identify, investigate, and report potential fraud and misconduct."

---

Part 1 — Conflict of interest

A conflict exists before anyone does anything wrong

The test is whether a reasonable observer would judge that the secondary interest could bias the primary judgement, not whether bias actually occurred. An investigator holding equity in the sponsor has a conflict on the day the trial opens, even if every subsequent decision is impeccable. This is why "I would never let it affect me" is never an adequate response — it answers a question nobody asked.

Financial and non-financial conflicts

Exam Watchout: The dual role of clinician and investigator is the conflict the exam returns to most. It is not prohibited — it is normal and often necessary — but it must be managed, usually by having someone other than the treating physician conduct the consent discussion so the participant does not feel that declining will damage their care. It also underlies therapeutic misconception, discussed in section 7.2.

What the source documents require

The disclose → assess → manage sequence

1. DISCLOSE   Investigator, sub-investigators and key staff declare interests
              to the institution, the sponsor and the IRB/IEC — at start-up
              and whenever circumstances change
                    │
2. ASSESS     Institutional COI committee / IRB/IEC judge whether the interest
              could reasonably bias the trial
                    │
3. MANAGE     Choose a proportionate control:
              • Disclose in the consent form and in publications
              • Independent consent-taker
              • Independent adjudication of endpoints
              • Reduce or divest the financial interest
              • Recuse from specific decisions
              • In the extreme: the individual does not take the role
                    │
4. MONITOR    Re-declare periodically; changes are reported, not assumed benign

Disclosure alone is management only for minor interests. A significant equity stake is not neutralised by a sentence in a consent form.

---

Part 2 — Research misconduct and fraud

The standard definition

Research misconduct is conventionally defined as fabrication, falsification or plagiarism in proposing, performing or reviewing research, or in reporting results:

Honest error and differences of scientific opinion are expressly not misconduct. A transcription mistake corrected through the audit trail is a data quality issue, not fraud. The distinguishing feature of misconduct is intent to deceive.

Related integrity failures

• Eligibility gaming — repeating a screening test until a value falls in range without protocol authorisation, or omitting a documented exclusion.
• Consent violations — signing on behalf of a participant, consenting after procedures have begun, using a superseded consent version knowingly.
• Ghost or guest authorship and selective reporting of favourable outcomes.
• Financial fraud — invoicing the sponsor for visits or procedures that did not occur.

Signals that surface fraud

Fraud is usually detected through patterns, not confessions. Central and centralised monitoring exists partly for this reason:

Exam Watchout: The correct action on suspicion is preserve, report, do not confront. A coordinator or monitor who challenges the suspected individual directly risks the destruction of evidence and may compromise a formal investigation. Secure the records — including electronic audit trails — and escalate through the defined route.

---

Escalation under ICH E6(R3)

Annex 1 section 3.12 sets out the pathway, and it distinguishes ordinary from serious noncompliance:

Principle 6.3 sits behind all of this: strategies must avoid, detect, address and prevent recurrence of serious noncompliance. Detection is an obligation, not a matter of luck.

---

Realistic exam scenario

Scenario: A monitor performing source data verification at a high-enrolling site notices that eight participants' diary cards are completed in what appears to be the same handwriting and ink, that all eight report exactly 100% dosing compliance, and that four have identical free-text comments. The site's principal investigator is also the participants' treating cardiologist, holds share options in the sponsor that were declared to the institution but do not appear in the consent form, and receives a per-participant payment noticeably higher than the visit workload appears to justify.

Evaluation — two distinct problems that must not be merged:

• The conflict of interest is a disclosure and management failure. Under the 2024 Declaration of Helsinki, funding sources and potential conflicts belong in the protocol (paragraph 22) and must be disclosed to participants during consent (paragraph 26). The share options were declared institutionally but not to participants, and the dual clinician–investigator role compounds the problem. This is remedied by amending the consent form with IRB/IEC approval, introducing an independent consent-taker, and having the institution's COI committee reassess the arrangement — including whether the per-participant payment is justifiable against actual effort.
• The diary cards are a possible misconduct signal — identical handwriting, implausible perfection and duplicated free text together suggest fabrication. This is not resolved by disclosure.

Correct actions: do not confront the investigator or site staff. Preserve the diary cards and secure the relevant electronic audit trails. Escalate immediately to the sponsor per the monitoring plan and the site's misconduct procedure. Expect the sponsor to perform a root cause analysis and, if the finding is confirmed as serious noncompliance under 3.12.2, to notify the regulatory authority and/or IRB/IEC, implement CAPA, assess the reliability of that site's data for the analysis, and consider whether participants were placed at risk. If the noncompliance persists after remediation, 3.12.3 puts termination of the site on the table. Handle the conflict of interest through its own disclosure and management track in parallel.